Lingohr Asset Management GmbH Takes Position in Qiagen N.V. $QGEN

Lingohr Asset Management GmbH acquired a new position in shares of Qiagen N.V. (NYSE:QGEN) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 94,400 shares of the company’s stock, valued at approximately $4,218,000.

Other hedge funds have also recently bought and sold shares of the company. MAI Capital Management boosted its holdings in shares of Qiagen by 998.9% during the second quarter. MAI Capital Management now owns 978 shares of the company’s stock worth $47,000 after purchasing an additional 889 shares during the last quarter. Farther Finance Advisors LLC boosted its stake in Qiagen by 400.5% in the 2nd quarter. Farther Finance Advisors LLC now owns 1,061 shares of the company’s stock worth $51,000 after buying an additional 849 shares during the last quarter. Allworth Financial LP grew its holdings in Qiagen by 260.1% in the 2nd quarter. Allworth Financial LP now owns 1,102 shares of the company’s stock valued at $53,000 after buying an additional 796 shares during the period. GAMMA Investing LLC increased its stake in shares of Qiagen by 375.5% during the 3rd quarter. GAMMA Investing LLC now owns 1,241 shares of the company’s stock valued at $55,000 after acquiring an additional 980 shares during the last quarter. Finally, Cullen Frost Bankers Inc. increased its stake in shares of Qiagen by 13,144.4% during the 2nd quarter. Cullen Frost Bankers Inc. now owns 1,192 shares of the company’s stock valued at $57,000 after acquiring an additional 1,183 shares during the last quarter. Institutional investors and hedge funds own 70.00% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on QGEN. Barclays reiterated an “overweight” rating and issued a $57.89 target price (up previously from $55.79) on shares of Qiagen in a report on Monday, December 15th. Deutsche Bank Aktiengesellschaft downgraded shares of Qiagen from a “buy” rating to a “hold” rating and lifted their price target for the stock from $52.00 to $54.00 in a research note on Thursday, January 22nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Qiagen in a research report on Monday, December 29th. Citigroup downgraded Qiagen from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $57.89 to $52.63 in a research note on Thursday, December 11th. Finally, Wall Street Zen cut shares of Qiagen from a “buy” rating to a “hold” rating in a report on Saturday, January 10th. Two investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $53.04.

Qiagen Trading Down 0.1%

NYSE:QGEN opened at $53.63 on Friday. The stock has a market cap of $11.33 billion, a price-to-earnings ratio of 27.69, a PEG ratio of 2.56 and a beta of 0.66. The company has a debt-to-equity ratio of 0.45, a quick ratio of 2.30 and a current ratio of 2.60. Qiagen N.V. has a 1 year low of $39.61 and a 1 year high of $57.81. The business has a fifty day moving average of $49.53 and a 200-day moving average of $49.64.

Qiagen (NYSE:QGEN) last released its earnings results on Thursday, November 6th. The company reported $0.64 earnings per share for the quarter, topping analysts’ consensus estimates of $0.61 by $0.03. Qiagen had a return on equity of 14.80% and a net margin of 19.58%.The firm had revenue of $532.58 million during the quarter, compared to the consensus estimate of $525.68 million. During the same period in the prior year, the firm posted $0.60 earnings per share. The firm’s revenue for the quarter was up 6.2% compared to the same quarter last year. Equities analysts predict that Qiagen N.V. will post 2.26 earnings per share for the current year.

Qiagen Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library?preparation kits and proteomics solutions.